FDA grants priority review of Ariad cancer drug candidate
Ariad Pharmaceuticals Inc. said Wednesday that the Food and Drug Administration has decided to review its lead cancer drug candidate on an accelerated timetable.
Cambridge-based Ariad is working on a drug candidate called ponatinib, which is being developed to help patients with certain kinds of leukemia --- specifically, chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia.
The FDA has indicated that it expects to take action on Ariad’s drug application for ponatinib no later than March 27, Ariad said in its press release.
If approved, ponatinib would be Ariad’s first product on the market.Chris Reidy can be reached at firstname.lastname@example.org.